Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03168438
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Conditions
- Malignant Melanoma Stage IV
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03166397
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: Erwinia asparaginaseDrug: SorafenibDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
- Conditions
- Multiple MyelomaHematological Malignancy
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 43
- Registration Number
- NCT03159702
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
- Conditions
- Advanced Ovarian CancerMalignant Melanoma
- Interventions
- Drug: CyclophosphamideDrug: FludarabineProcedure: PembrolizumabBiological: Tumor-Infiltrating Lymphocytes (TILs)Biological: Interleukin-2 (IL-2)
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 8
- Registration Number
- NCT03158935
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
- Conditions
- B Cell Lymphoma
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03146533
- Locations
- 🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 16
- Registration Number
- NCT03139370
- Locations
- 🇺🇸
Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Conditions
- Acute LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaFollicular LymphomaGraft Versus Host DiseaseHodgkin LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic Syndrome
- Interventions
- Drug: BusulfanDrug: CyclophosphamideDrug: Fludarabine PhosphateProcedure: Hematopoietic Cell TransplantationOther: Laboratory Biomarker AnalysisDrug: Melphalan HydrochlorideDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT03128359
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclosporineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyRadiation: Pretargeted RadioimmunotherapyRadiation: Total-Body Irradiation
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT03128034
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
- Conditions
- Hematopoietic/Lymphoid CancerAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03126864
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.